LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

Autor:	B. Mellado Gonzalez, D. Castellano Gauna, Alejo Rodriguez-Vida, B. Perez Valderrama, Montserrat Domenech, Teresa Bonfill, J. Puente, M.A. Climent Duran, F.J. Vazquez Mazon, Pablo Maroto, J.L. Perez Gracia, A. Pinto Marin, R. Morales Barrera, O.J. Juan Vidal, I. Ballester Navarro, X. Garcia del Muro, Joaquim Bellmunt
Rok vydání:	2020
Předmět:	Cisplatin Oncology medicine.medical_specialty Metastatic Urothelial Carcinoma business.industry Hematology Gemcitabine Carboplatin law.invention Avelumab chemistry.chemical_compound Randomized controlled trial chemistry law Internal medicine medicine In patient business medicine.drug
Zdroj:	Annals of Oncology. 31:S1158-S1159
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.2256
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::06e83c4b51b40a03d75e10019986ebe4 https://doi.org/10.1016/j.annonc.2020.08.2256 Zobrazit plný text záznamu